These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 26701087)

  • 41. HER2-positive metastatic breast cancer: a changing scenario.
    Mustacchi G; Biganzoli L; Pronzato P; Montemurro F; Dambrosio M; Minelli M; Molteni L; Scaltriti L
    Crit Rev Oncol Hematol; 2015 Jul; 95(1):78-87. PubMed ID: 25748080
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer.
    Welslau M; Diéras V; Sohn JH; Hurvitz SA; Lalla D; Fang L; Althaus B; Guardino E; Miles D
    Cancer; 2014 Mar; 120(5):642-51. PubMed ID: 24222194
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunoconjugates in the treatment of breast cancer.
    Tripathy D
    Clin Adv Hematol Oncol; 2014 Jul; 12(7):469-72. PubMed ID: 25322329
    [No Abstract]   [Full Text] [Related]  

  • 44. HER2 testing in patients with breast cancer.
    Dixon JM; Wilson V; Verrill M; Symmans WF
    BMJ; 2012 Jun; 344():e3958. PubMed ID: 22689887
    [No Abstract]   [Full Text] [Related]  

  • 45. [Recent advances in targeted therapies in the treatment of HER2-positive metastatic breast cancer].
    Ismaili N; Belbaraka R; Elomrani A; Khouchani M; Tahri A
    Presse Med; 2013 Nov; 42(11):1461-8. PubMed ID: 23721860
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer.
    Junttila TT; Li G; Parsons K; Phillips GL; Sliwkowski MX
    Breast Cancer Res Treat; 2011 Jul; 128(2):347-56. PubMed ID: 20730488
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Does trastuzumab-emtansine have better cardiac safety profile in contrast to trastuzumab?
    Sendur MA; Aksoy S; Ozdemir Y; Zengin N; Altundag K
    J BUON; 2013; 18(3):801. PubMed ID: 24065505
    [No Abstract]   [Full Text] [Related]  

  • 48. Bevacizumab confers additional advantage to the combination of trastuzumab plus pertuzumab in trastuzumab‑refractory breast cancer model.
    Sun Y; Dey N; Brammer M; De P; Leyland-Jones B
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):733-45. PubMed ID: 23959459
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pertuzumab: a new anti-HER2 drug in the management of women with breast cancer.
    Dawood S; Sirohi B
    Future Oncol; 2015; 11(6):923-31. PubMed ID: 25760974
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer.
    Gupta M; Lorusso PM; Wang B; Yi JH; Burris HA; Beeram M; Modi S; Chu YW; Agresta S; Klencke B; Joshi A; Girish S
    J Clin Pharmacol; 2012 May; 52(5):691-703. PubMed ID: 21953571
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Monoclonal antibody therapy in breast cancer].
    Dank M; Tõkés T
    Magy Onkol; 2013 Sep; 57(3):157-65. PubMed ID: 24107821
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rapid response to trastuzumab emtansine in a patient with HER2-driven lung cancer.
    Weiler D; Diebold J; Strobel K; Aebi S; Gautschi O
    J Thorac Oncol; 2015 Apr; 10(4):e16-7. PubMed ID: 25789838
    [No Abstract]   [Full Text] [Related]  

  • 53. Targeted therapies: TH3RESA trial, overcoming hurdles in breast cancer.
    Villanueva MT
    Nat Rev Clin Oncol; 2014 Jul; 11(7):379. PubMed ID: 24913372
    [No Abstract]   [Full Text] [Related]  

  • 54. [Antibody-drug conjugate--a new age for personalized cancer treatment].
    Bertholjotti I
    Chimia (Aarau); 2011; 65(9):746-8. PubMed ID: 22026193
    [No Abstract]   [Full Text] [Related]  

  • 55. Technology evaluation: cantuzumab mertansine, ImmunoGen.
    Smith SV
    Curr Opin Mol Ther; 2004 Dec; 6(6):666-74. PubMed ID: 15663331
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In the spotlight: a novel CD37 antibody-drug conjugate.
    Palomba ML; Younes A
    Blood; 2013 Nov; 122(20):3397-8. PubMed ID: 24235129
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Smart Nanotransformers with Unique Enzyme-Inducible Structural Changes and Drug Release Properties.
    Bellat V; Lee HH; Vahdat L; Law B
    Biomacromolecules; 2016 Jun; 17(6):2040-9. PubMed ID: 27180972
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeted Maytansinoid Conjugate Improves Therapeutic Index for Metastatic Breast Cancer Cells.
    Jiang Z; Yang Z; Li F; Li Z; Fishkin N; Burgess K
    Bioconjug Chem; 2018 Sep; 29(9):2920-2926. PubMed ID: 30102524
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Blocking PD-1 in Tumors with Faulty DNA Repair.
    Cancer Discov; 2016 Aug; 6(8):OF6. PubMed ID: 27354272
    [TBL] [Abstract][Full Text] [Related]  

  • 60. T-DM1 extravasation: first description.
    Sibaud V; Nougarolis S; Borjesson C; Gangloff D; Delord JP; Pompa V; Saintenac D; Roche H
    J Eur Acad Dermatol Venereol; 2016 Jul; 30(7):1235-6. PubMed ID: 25879278
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.